Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Financing Activities (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Cash from Financing Activities readings, the most recent being $2.6 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 13.12% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$43.4 million, a 618.31% decrease, with the full-year FY2025 number at -$43.4 million, down 618.31% from a year prior.
  • Cash from Financing Activities hit $2.6 million in Q4 2025 for Tandem Diabetes Care, up from -$1.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $18.8 million in Q3 2021 to a low of -$39.7 million in Q2 2025.
  • Median Cash from Financing Activities over the past 5 years was $2.6 million (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 2611.28% in 2024 and later crashed 1222.88% in 2025.
  • Tandem Diabetes Care's Cash from Financing Activities stood at $15.9 million in 2021, then tumbled by 61.6% to $6.1 million in 2022, then plummeted by 57.1% to $2.6 million in 2023, then fell by 12.04% to $2.3 million in 2024, then increased by 13.12% to $2.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were $2.6 million (Q4 2025), -$1.6 million (Q3 2025), and -$39.7 million (Q2 2025) per Business Quant data.